Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

Summary

Patients will be enrolled in two stages: * Dose-escalation stage: Approximately 12-24 patients will be enrolled.

Timeline

Start

2018-06-20

Primary completion

2020-09-25

Completion

2020-09-25

Publications

• Jang H, Kim JY, Kim S, Kim H, Byun MS, Lee MA, Chang JH, Nam DH, Kim TW, Jeun SS, Sohn JH, Park SH, Shin EC. Long-acting IL-7 induces distinct transcriptomic features in peripheral T cells of patients with solid tumors. JCI Insight. 2026 Apr 21;11(11):e203629. doi: 10.1172/jci.insight.203629. eCollection 2026 Jun 8.

Drugs

Indications